Aimei Health Technology Co., Ltd.

Overview

Compare with another stock.

• TickerAFJK on Nasdaq¹
• IndustryBlank Checks¹
• HeadquartersNew York, New York¹
• Business address10 East 53Rd Street, Suite 3001, New York, Ny 10022²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

“Company” and to “we,” “us,” and “our” refer to Aimei Health Technology Co., Ltd.³ From its latest annual report

Corporate structure

Aimei Health Technology Co., Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aimei Health Technology Co., Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our executive offices are located at 10 East 53rd Street, Suite 3001, New York, NY 10022, and our telephone number is 86-13758131392.

The Sponsor has agreed, commencing from the date that our securities were first listed on the Nasdaq Global Market (“Nasdaq”), through the earlier of our consummation of an initial business combination and our liquidation, to make available to us certain general and administrative services, including office space, utilities, and administrative services, as we may require from time to time. We have agreed to pay to the Sponsor, $10,000 per month, for up to 12 months, subject to extension to up to 36 months, for such administrative services. As of December 31, 2025, the unpaid balance was $240,000, which was included in amount due to related party balance.

Item 2 of the 10-K filed May 4, 2026.³

Leadership

Who has led Aimei Health Technology Co., Ltd., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJuan Fernandez Pascual Nov 30, 2023 to Nov 30, 2023⁸
• Chief financial officerHeung Ming Henry Wong Nov 30, 2023 to Nov 30, 2023⁹

Timeline

1. Oct 5, 20268-K New debt or obligation¹³
2. Sep 3, 20268-K New debt or obligation¹⁴
3. Aug 25, 20268-K Listing notice or transfer¹⁵
4. Aug 6, 20268-K New debt or obligation¹⁶
5. Jul 8, 20268-K Ended a material agreement; Regulation FD disclosure¹⁷
6. Jul 6, 20268-K New debt or obligation¹⁸
7. Jun 29, 20268-K Executive or director change¹⁹
8. Jun 4, 20268-K New debt or obligation²⁰
9. May 20, 20268-K Listing notice or transfer²¹
10. May 6, 20268-K New debt or obligation²²
11. Apr 21, 20268-K Listing notice or transfer²³
12. Apr 7, 20268-K New debt or obligation²⁴
13. Nov 30, 2023New chief executive Juan Fernandez Pascual becomes CEO⁸

Calendar

Coming up

1. Nov 17, 2026Reports results for the quarter ending Sep/2026²⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

122 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 38 major events, 10 insider forms, 30 large holders, 32 other. The latest 20:

1. Oct 9, 2026PRE 14A EDGAR
2. Oct 5, 20268-K EDGAR
3. Sep 3, 20268-K EDGAR
4. Aug 25, 20268-K EDGAR
5. Aug 13, 202610-Q EDGAR
6. Aug 10, 2026SCHEDULE 13G/A EDGAR
7. Aug 6, 20268-K EDGAR
8. Aug 5, 2026SCHEDULE 13G/A EDGAR
9. Jul 8, 20268-K EDGAR
10. Jul 6, 20268-K EDGAR
11. Jul 1, 20263 EDGAR
12. Jun 29, 20268-K EDGAR
13. Jun 16, 202610-Q EDGAR
14. Jun 4, 20268-K EDGAR
15. May 20, 20268-K EDGAR
16. May 6, 20268-K EDGAR
17. May 4, 202610-K EDGAR
18. Apr 21, 20268-K EDGAR
19. Apr 7, 20268-K EDGAR
20. Apr 1, 2026NT 10-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 1 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• First Trust Capital Management L.P.SCHEDULE 13G/A, 3 filings Nov 14, 2024 to Aug 10, 2026²⁶
• W. R. BerkleySCHEDULE 13G/A, 3 filings Apr 8, 2025 to Aug 5, 2026²⁷
• Mizuho Financial GroupSCHEDULE 13G/A, 4 filings Feb 13, 2025 to Feb 12, 2026²⁸
• Karpus Management, Inc.SCHEDULE 13G/A, 3 filings Apr 9, 2024 to Jan 7, 2026²⁹
• WOLVERINE ASSET MANAGEMENT LLCSCHEDULE 13G/A, 5 filings Feb 8, 2024 to Nov 7, 2025³⁰
• GLAZER CAPITAL, LLCSCHEDULE 13G, 4 filings Feb 14, 2024 to Feb 14, 2025³¹
• Wealthspring Capital LLCSCHEDULE 13G/A, 2 filings Mar 8, 2024 to Feb 13, 2025³²
• COWEN AND COMPANY, LLCSC 13G/A, 2 filings Feb 2, 2024 to Nov 13, 2024³³
• Harraden Circle Investments, LLCSC 13G/A, 3 filings Dec 8, 2023 to Nov 13, 2024³⁴
• Aimei Investment LtdSC 13D, 1 filing Dec 15, 2023³⁵

SEC filer profile

How Aimei Health Technology Co., Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAimei Health Technology Co., Ltd.¹
• CIK0001979005
• Employer ID (EIN)00-0000000³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inCayman Islands³
• Fiscal year endsDecember 31¹
• Industry code (SIC)6770 Blank Checks¹
• SEC reviewing officeOffice of Real Estate & Construction, Division of Corporation Finance¹
• Business address10 East 53Rd Street, Suite 3001, New York, NY 10022¹
• Phone34 678 035200¹
• Shares outstanding3,166,332 as of Aug 13, 2026⁶
• Public float$44.6M as of Jun 30, 2025³
• AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceMay 26, 2023¹
• Filings122 in all: 8-K (38), SCHEDULE 13G/A (12), SC 13G (9), 10-Q (8), 3 (8), CORRESP (5), S-1/A (5), UPLOAD (5)¹
  All 24 form types

  DEF 14A (4), PRE 14A (4), SC 13G/A (4), SCHEDULE 13G (4), 10-K (3), 4 (2), DEFA14A (2), 10-K/A (1), 424B4 (1), 8-A12B (1), CERT (1), EFFECT (1), NT 10-K (1), NT 10-Q (1), S-1 (1), SC 13D (1)

• Latest filingsAnnual report (10-K) May 4, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Nov 10, 2025
  Latest 8-K (8-K) Oct 5, 2026

Securities registered for trading

From the cover page of the 10-K filed May 4, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks Aimei Health Technology Co., Ltd. names in Item 1A of its 10-K filed May 4, 2026: 3 risks under these headings, as written.³

• Geopolitical conflicts involving Iran, military actions in the Middle East, and the war in Ukraine may adversely affect global economic conditions and cause significant volatility in the trading price of our ordinary shares.
• Our securities may be suspended or delisted from Nasdaq and could trade on the over-the-counter (“OTC”) market, which could materially reduce liquidity and the value of our securities.
• Ongoing uncertainty and delay in obtaining CSRC approval for the proposed Business Combination, together with the limited time remaining to complete an alternative transaction, may prevent us from consummating a business combination before our outside date and could result in our liquidation.

Legal proceedings

We may be subject to legal proceedings, investigations, and claims incidental to the conduct of our business from time to time. We are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim that has a more than remote possibility of having a material adverse effect on our business, financial condition, or results of operations.

The opening of Item 3, Legal Proceedings.³